Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EPS (Weighted Average and Diluted) (2021 - 2025)

TScan Therapeutics (TCRX) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.18 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 40.0% to -$0.18 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 through Dec 2025, up 13.04% year-over-year, with the annual reading at -$1.0 for FY2025, 12.28% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.18 at TScan Therapeutics, up from -$0.28 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.38 in Q4 2021, with the low at -$7.69 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.78, with a median of -$0.3 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 91.81% in 2022, while the deepest fall reached 302.63% in 2022.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at $0.38 in 2021, then plummeted by 302.63% to -$0.77 in 2022, then skyrocketed by 85.71% to -$0.11 in 2023, then crashed by 172.73% to -$0.3 in 2024, then soared by 40.0% to -$0.18 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.18, -$0.28, and -$0.28 for Q4 2025, Q3 2025, and Q2 2025 respectively.